Nurix Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Net Income	-264.46	-193.57	-143.95	-180.36	-117.19
Depreciation & Amortization	18.86	16.43	13.65	10.81	6.08
Stock-Based Compensation	37.97	33.93	33.67	28.13	15.8
Other Adjustments	-10.23	-11.26	-4.58	0.64	1.83
Change in Receivables	-	-	-	6	-6
Changes in Accounts Payable	-0.63	5.21	1.61	0.09	1.59
Changes in Accrued Expenses	17.31	11.82	3.12	7.49	6.22
Changes in Unearned Revenue	-36.98	-28.55	19.51	-26.63	14.25
Changes in Other Operating Activities	-11.3	-6.88	-4.13	-5.97	-6.94
Operating Cash Flow	-249.47	-172.87	-81.08	-159.81	-84.37
Capital Expenditures	-14	-9.27	-8.4	-12.24	-5.66
Purchases of Investments	-455.69	-707.95	-246.33	-239.37	-348.5
Proceeds from Sale of Investments	617.54	459.51	323.04	278.81	245.91
Investing Cash Flow	147.85	-257.71	68.3	27.2	-108.25
Issuance of Common Stock	238.64	485.68	3.22	117.19	153.88
Repurchase of Common Stock	-	-0.02	-	-	-0
Net Common Stock Issued (Repurchased)	238.64	485.67	3.22	117.19	153.88
Financing Cash Flow	238.64	485.67	3.22	117.19	153.88
Net Cash Flow	137.03	55.37	-9.85	-15.42	-38.73
Free Cash Flow	-263.47	-182.14	-89.48	-172.05	-90.03
FCF Margin	-313.73%	-333.91%	-116.23%	-445.42%	-302.61%
Free Cash Flow Per Share	-3.04	-2.71	-1.65	-3.54	-2.10
Levered Free Cash Flow	-291.2	-204.82	-118.57	-206.82	-101.66
Unlevered Free Cash Flow	-313.23	-224.57	-129.69	-210.33	-102.48

Updated Nov 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q